Clinical Edge Journal Scan

Dupilumab maintains efficacy despite dose reduction in persistently-controlled atopic dermatitis


 

Key clinical point : Reduction in dupilumab dose to every 3 or 4 weeks does not decrease its efficacy in patients with persistently-controlled atopic dermatitis (AD), with clinical outcome measures remaining stable over time.

Major finding: After 144 weeks, similar to patients receiving 300 mg dupilumab every 2 weeks, those receiving 300 mg dupilumab every 3 and 4 weeks had significantly decreased mean Eczema Area and Severity Index, Severity Scoring of Atopic Dermatitis, Pruritus Numerical Rating Scale, and Sleep Numerical Rating Scale scores (all P < .05).

Study details: This multicenter retrospective observational study included 54 patients age ≥ 16 years with controlled moderate-to-severe AD treated with dupilumab for ≥ 1 year who were assigned to receive 300 mg dupilumab every 2 weeks (n = 27), 3 weeks (n = 17), or 4 weeks (n = 10).

Disclosures: This study received no specific funding from any sources. The authors declared no conflicts of interest.

Source: Sánchez-García V et al. Evaluation of dupilumab dosing regimen in patients with persistently controlled atopic dermatitis. J Eur Acad Dermatol Venereol. 2023 (Jul 17). doi: 10.1111/jdv.19348

Recommended Reading

Commentary: Abrocitinib, Malignancy Risk, and S aureus in AD, August 2023
MDedge Dermatology
Free teledermatology clinic helps underserved patients initiate AD care
MDedge Dermatology
Economic Burden and Quality of Life of Patients With Moderate to Severe Atopic Dermatitis in a Tertiary Care Hospital in Helsinki, Finland: A Survey-Based Study
MDedge Dermatology
Nemolizumab shows promise in pediatric atopic dermatitis with inadequately controlled pruritus
MDedge Dermatology
Amlitelimab is effective and well-tolerated in atopic dermatitis inadequately controlled by topical therapies
MDedge Dermatology
Continuous upadacitinib treatment required to maintain skin clearance in atopic dermatitis
MDedge Dermatology
Abrocitinib is safe and effective against difficult-to-treat atopic dermatitis in daily practice
MDedge Dermatology
Cannabis use is more prevalent in patients with atopic dermatitis
MDedge Dermatology
Early emollient bathing is tied to the development of atopic dermatitis by 2 years of age
MDedge Dermatology
Dupilumab + TCS confers rapid and sustained improvement in atopic dermatitis severity in children
MDedge Dermatology